310210 - Voronoi, Inc.

310210 Summary
Biopharma
Stock Price & Overview
₩153,000 +5,800 (+3.94%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩153,000  ≈ US$109  ·  Market cap ₩2.8tn (≈ $2.0bn)
Why this page exists. Korean issuers file to DART, not the SEC, and almost nothing is published in English. Titles here are translated; where kstock has read the filing, the row carries the explanation and the amount in won and dollars. How we pick »

310210 DART Filings

DART

Material matter affecting investment judgment (clinical trial plan amendment approved)

Filing08/18/26title translated
DART

Half-Year Report

Periodic08/14/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing08/07/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment approved)

Filing07/31/26title translated
DART

Designation of who may exercise the call option on convertible bonds

Filing07/30/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing07/08/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing06/25/26title translated
DART

Repurchase of its own convertible bonds before maturity

Filing06/24/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing06/23/26title translated
DART

Repurchase of its own convertible bonds before maturity

Filing06/23/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing06/22/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing06/10/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment approved)

Filing05/27/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing05/26/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Designation of who may exercise the call option on convertible bonds

Filing05/08/26title translated
13 routine filings (insider holdings reports, IR schedules)DART

5% Ownership Report — Large Holdings

Ownership08/31/26title translated
DART

5% Ownership Report — Large Holdings

Ownership08/28/26title translated
DART

Investor Relations Event

IR08/21/26title translated
DART

Investor Relations Event

IR07/06/26title translated
DART

Insider / Major Shareholder Holdings Report ×4

Ownership07/03/26title translated
DART

5% Ownership Report — Large Holdings

Ownership07/03/26title translated
DART

Investor Relations Event

IR06/23/26title translated
DART

5% Ownership Report — Large Holdings

Ownership06/22/26title translated
DART

5% Ownership Report — Large Holdings

Ownership06/08/26title translated
DART

Insider / Major Shareholder Holdings Report ×2

Ownership06/08/26title translated
DART

Investor Relations Event

IR06/02/26title translated
DART

5% Ownership Report — Large Holdings

Ownership05/27/26title translated
DART

Investor Relations Event

IR05/13/26title translated
29 filings on file, grouped where one event produced many. Source: DART, operated by Korea's Financial Supervisory Service.

Similar to 310210

SymbolLast Price
000250Samchundang Pharm₩157,000
+1.0%
087010Peptron, Inc.₩157,300
+7.3%
141080LigaChem Biosciences Inc.₩92,000
+4.2%
145020Hugel, Inc.₩244,000
+1.5%
302440SK Bioscience Co., Ltd.₩37,900
+0.4%
009420Hanall Biopharma Co., Ltd.₩54,700
+1.5%
214370Caregen Co., Ltd.₩44,500
+1.5%
347850D & D Pharmatech, Inc.₩49,200
+1.4%
237690ST Pharm Co., Ltd.₩101,200
+2.2%
226950Olix Pharmaceuticals, Inc.₩95,900
+4.5%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.